Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04402788 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

StatusSuspended
PhasePhase 2/3
Started2021-01-07
View on ClinicalTrials.gov ↗
This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of small cell lung cancer that has spread outside of the lung or to other parts of the body (extensive stage). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving radiation therapy in addition to atezolizumab may extend the time without extensive small cell lung cancer growing or spreading compared to atezolizumab alone.

Amendment history 2 changes detected by DataLookout

2026-09-04
critical
Recruitment suspended: Scheduled Interim Monitoring
2026-09-04
minor
Trial sites reduced: 415 → 411 locations
Trial Details
NCT Number NCT04402788
Lead Sponsor National Cancer Institute (NCI)
Collaborators: NRG Oncology
Conditions Extensive Stage Lung Small Cell Carcinoma
Enrollment 138 participants
Start Date 2021-01-07
Primary Completion 2027-04-30 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-09-04